RecruitingPhase 3NCT05764044
Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer
Studying Plasma cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospital do Coracao
- Intervention
- cisplatin, gemcitabine(drug)
- Enrollment
- 365 enrolled
- Eligibility
- 18-70 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (26)
- Centro Integrado de Pesquisa da Amazônia, CINPAM, Manaus, Amazonas, Brazil
- Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Espírito Santo, Brazil
- Hospital Samur, Vitória da Conquista, Estado de Bahia, Brazil
- Hospital de Base do Distrito Federal, Brasília, Federal District, Brazil
- Hospital do Câncer de Muriaé, Muriaé, Minas Gerais, Brazil
- Centro de Oncologia de Cascavel, CEONC, Cascavel, Paraná, Brazil
- União Oeste Paranaense de Estudos e Combate ao Câncer, UOPECCAN, Cascavel, Paraná, Brazil
- Centro Integrado de Oncologia de Curitiba, CIONC, Curitiba, Paraná, Brazil
- Instituto Nacional do Câncer, INCA, Rio de Janeiro, Rio de Janeiro, Brazil
- Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande do Norte, Brazil
- Hospital Tacchini, Bento Gonçalves, Rio Grande do Sul, Brazil
- Hospital Geral de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil
- Hospital Bruno Born, Lajeado, Rio Grande do Sul, Brazil
- Centro Gaúcho Integrado Hospital Mãe de Deus, Porto Alegre, Rio Grande do Sul, Brazil
- Centro Oncologico de Roraima, CECOR, Boa Vista, Roraima, Brazil
- +11 more locations on ClinicalTrials.gov
Collaborators
University of Sao Paulo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05764044 on ClinicalTrials.govOther trials for Plasma cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07446777FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami
- RECRUITINGPHASE1NCT07333261Study of BMS-986453 in Newly Diagnosed Multiple MyelomaSusan Bal
- RECRUITINGPHASE3NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC
- RECRUITINGPHASE1NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaMedical College of Wisconsin
- RECRUITINGPHASE2NCT06920251Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapySeoul National University Hospital
- RECRUITINGPHASE2NCT06822972HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMDuke University
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07210047Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsHuniLife Biotechnology, Inc.
- RECRUITINGNANCT07045727Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaMayo Clinic